SureTrader Stock Hero Advertisement SPDR Advertisement
Home > Boards > US Listed > Biotechs >

MultiCell Technologies (MCET)

Add MCET Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator MyDogBuster, Dip66, locksflooring, HorseShoe Man, sup105
Search This Board:
Last Post: 3/5/2015 1:12:41 PM - Followers: 577 - Board type: Free - Posts Today: 14
MultiCell Technologies (MCET) 
68 Cumberland Street, Suite 301
Woonsocket, RI 02895
 Office: (401) 762-0045



Ticker - MCET (U.S. Reporting: SEC Filer) 

Estimated outstanding shares: 4.3 Billion a/o October 2014

Estimated Float: 3.97 Billion a/o October 2014

(This "Intro Box" is NOT maintained by MultiCell Technologies and is intended solely as a quick information source on ihub.  For more detailed, up-to-date information on MultiCell Technologies,  please go the company website.)



Therapeutic Pipeline

MultiCell Technologies’ portfolio of lead drug candidates is in various stages of preclinical and clinical development

 MCT-125, a Phase 2 therapeutic candidate for the treatment of PMSF which has demonstrated efficacy in a 138 patient Phase IIa clinical trial.

                                       MCT-465, a preclinical synthetic dsRNA therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers such as those expressing TLR-3.

 MCT-475, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of certain cancers.

 MCT-485, a discovery stage dsRNA therapeutic candidate for the treatment of certain cancers.

Therapeutic Candidate  


Discovery Optimization    

Preclinical Development    

Phase 1    

Phase 2/b   

Phase 3    



X X X X  



X X      



X X      



X X      

Patent Portfolio of MultiCell Technologies, Inc., MultiCell Immunotherapeutics and majority-owned subsidiary, Xenogenics. Patents already published which can be found in the public domain.

MultiCell Technologies, Inc. Corporate Headquarters

MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer.

Our therapeutic development platform relies on several patented technologies used to: (i) isolate, characterize and differentiate stem cells from human liver, or (ii) control the immune response at transcriptional and translational levels through dsRNA-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, or (iii) generate specific and potent immunity against key tumor targets through a novel immunoglobulin platform technology, or (iv) modulate the noradrenaline-adrenaline neurotransmitter pathway.

Our most advanced lead drug candidate, MCT-125, is an oral small molecule drug combination which targets the noradrenaline-adrenaline neurotransmitter pathway for the treatment of primary multiple sclerosis-related fatigue (PMSF). Primary multiple sclerosis-related fatigue (PMSF) affects over 70% of all persons with multiple sclerosis (MS). MCT-125 has demonstrated efficacy in a 138 patient Phase 2a clinical trial for the treatment of PMSF.

While significant progress has been made in developing cancer therapies that result in tumor regression, the control of cancer over a longer interval and especially of metastatic disease, remains a key goal. MultiCell is also developing novel therapeutics for the treatment of cancer. MCT-465, MCT-475 and MCT-485 are the first of a family of prospective cancer therapeutics based on the use of our patented therapeutic antibody and synthetic dsRNA technologies. MCT-465, a potent immune enhancer, is indicated as an cancer adjuvant therapy alone or combined with currently available or novel therapies. MCT-465 can also be used with our MCT-475 antibody therapeutic for the treatment of various cancers such as breast carcinoma. MCT-485, a cytotoxic agent, is a novel synthetic dsRNA with therapeutic properties distinct from those of MCT-465, and is indicated for the treatment of certain cancers. MCT-465 is in early-stage preclinical development, and MCT-475 and MCT-485 are in the discovery optimization stage of development.

The role liver stem cells play in the carcinogenic process has recently led to a new hypothesis that hepatocellular carcinoma arises by maturation arrest of liver stem cells. MultiCell is developing therapeutic product opportunities specifically targeting the treatment of hepatocellular carcinoma and intrahepatic bile duct cancer by leveraging our synthetic dsRNA and antibody therapeutic platforms against cancer stem cells. MultiCell owns exclusive rights to two issued U.S. patents (6,872,389 and 6,129,911), and several corresponding issued and pending patents and patent applications related to the isolation and differentation of liver stem cells.

Find us on Google Maps  

 Management and Board of Directors

Barbara (Corbett) Newmin - Investor Relations

W. Gerald Newmin, Chairman and Chief Executive Officer
Mr. W. Gerald Newmin joined the Company in June 1995.  Mr. Newmin currently serves as Chairman of the Board of Directors and Acting Chief Executive Officer of the Company.  Mr. Newmin is also Chairman and CEO, and a director of Xenogenics Corporation, a majority-owned subsidiary of the Company; Chairman and CEO, and a director of MCT Rhode Island Corp., a wholly-owned subsidiary of the Company; and, CEO and a director of MultiCell Immunotherapeutics, Inc., a majority-owned subsidiary of the Company.  Mr. Newmin has managed NYSE and American Stock Exchange Fortune 500 companies.  Mr. Newmin has been President of Health America Corporation, then the nation’s largest publicly held HMO management company.  Mr. Newmin was Chief Executive Officer and President of The International Silver Company, a diversified multi-national manufacturing company that he restructured.  Mr. Newmin was Chief Operating Officer of numerous Whittaker Corporation operating units, including Production Steel Company, Whittaker Textiles, Bertram Yacht, Trojan Yacht, Columbia Yacht, Narmco Materials and Anson Automotive.  Mr. Newmin was instrumental in Whittaker’s entry into the US and international health care markets.  Mr. Newmin was Western Regional Vice President of American Medicorp, Inc, where he managed 23 acute care hospitals in the Western United States.  Mr. Newmin retired as Chairman and Chief Executive Officer of SYS Technologies, Inc., a high-growth defense technology company in 2003.  Mr. Newmin has a Bachelors degree in Accounting from Michigan State University.



  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
MCET News: Statement of Ownership (sc 13g) 02/17/2015 07:24:44 AM
MCET News: Additional Proxy Soliciting Materials (definitive) (defa14a) 02/10/2015 08:50:16 AM
MCET News: Additional Proxy Soliciting Materials (definitive) (defa14a) 02/04/2015 04:42:25 PM
MCET News: Additional Proxy Soliciting Materials (definitive) (defa14a) 01/23/2015 04:36:20 PM
MCET News: Proxy Statement (definitive) (def 14a) 12/12/2014 03:03:36 PM
#39289  Sticky Note Voting Right e-mail sup105 01/21/15 03:00:13 PM
#34376  Sticky Note MultiCell Technologies, Inc. OTCQB TraderpennyX 04/03/14 03:57:31 AM
#39441   I see you did learn. Good for you! roberteliates 03/05/15 01:12:41 PM
#39440   MCET is a Penny. Learn to trade roberteliates 03/05/15 01:10:42 PM
#39439   Just because you made money in the past simon wagstaff 03/05/15 01:05:51 PM
#39438   Well said TrippleJ. sharki 03/05/15 12:06:49 PM
#39437   Lol! simon wagstaff 03/05/15 11:40:32 AM
#39435   I have made money on this stock every TripleJ 03/05/15 11:38:28 AM
#39434   You don't invest in MCET, you play a simon wagstaff 03/05/15 11:07:44 AM
#39433   I have been investing in this company for TripleJ 03/05/15 10:45:24 AM
#39432   I've known for years and my posts get simon wagstaff 03/05/15 09:57:50 AM
#39431   221,000,000 millions on the bid something fishy is redsox17 03/05/15 09:54:01 AM
#39430   How many investors here and what's your share Turtledip 03/05/15 09:18:31 AM
#39429   The writing was on the wall when Barbie Dip66 03/05/15 08:49:46 AM
#39428   Why? It's free money we should be ashamed Turtledip 03/05/15 01:05:52 AM
#39425   MANAGEMENT SHOULD BE ASHAMED OF THEMSELVES ! locksflooring 03/04/15 05:01:01 PM
#39424   La Jolla interest in MCET oneifbylan 03/04/15 03:44:29 PM
#39423   If they are successful in increasing the total ztek 03/04/15 02:50:54 PM
#39422   Last Price: 0002$ who would have ever thought, Dip66 03/04/15 02:47:34 PM
#39421   I'm obviously in the wrong business; everyone should Dip66 03/04/15 12:35:49 AM
#39420   From the looks of the 10K that came Brock69 03/03/15 03:53:37 PM
#39417   Can anyone pls ask company when they will newlonginvest 03/03/15 01:17:06 PM
#39416   Read to me we got good news coming Turtledip 03/02/15 05:27:47 PM
#39415   Form 10-K OUT! TraderpennyX 03/02/15 03:42:58 PM
#39414 ZTPorto 03/02/15 02:58:31 PM
#39413   Company is sleeping .. How can we awake newlonginvest 03/02/15 12:38:28 PM
#39412   Doesn't this have to get to the Par bontooth 03/02/15 12:04:16 PM
#39411   Complete change of management needed asap. Dip66 03/02/15 10:39:04 AM
#39410   imo . . Until we see new faces bontooth 03/02/15 10:11:42 AM
#39409   Is this the week Mr. NEWMIN helps the HorseShoe Man 03/02/15 08:34:34 AM
#39408   What I am wondering is who is going Dip66 03/02/15 12:22:39 AM
#39407   February 5, 2015 Dip66 03/01/15 06:17:24 PM
#39406   not really sure. just a feeling . but Tambra3077 03/01/15 04:02:18 PM
#39405   . .Post #39389 bontooth 03/01/15 02:11:49 PM
#39404   That's everyday lol I come to message boards Turtledip 02/27/15 05:56:24 PM
#39403   No action today HorseShoe Man 02/27/15 12:47:08 PM
#39402   Funny trading today as if someone knows something HorseShoe Man 02/26/15 03:26:26 PM
#39401   I knew, years ago. Lol! simon wagstaff 02/26/15 02:51:28 PM
#39400   Jerald Newmin Dip66 02/26/15 01:07:32 PM
#39399   Someone's cleaning up here! Big payday for someone HorseShoe Man 02/26/15 12:46:03 PM
#39398   Here she goes HorseShoe Man 02/26/15 12:38:28 PM
#39397   Big volume today already. Will we see HorseShoe Man 02/26/15 12:34:07 PM
#39396   And the buying continues today? ?? HorseShoe Man 02/26/15 11:48:03 AM
#39395   A lot of buying today HorseShoe Man 02/25/15 06:54:24 PM
#39394   Why CEO is not ashamed of this dillution newlonginvest 02/25/15 06:30:15 PM
#39393   Saw that coming HorseShoe Man 02/25/15 01:58:14 PM
#39392   No surprise no surprise. This is where HorseShoe Man 02/25/15 01:20:59 PM
#39391   No surprise on these big share buys. This HorseShoe Man 02/25/15 01:06:55 PM
#39390   Something is happening HorseShoe Man 02/25/15 11:35:34 AM
#39389   starting to feel concerned here Tambra3077 02/25/15 11:35:01 AM
#39388   I'm new here and i'm in HorseShoe Man 02/25/15 06:16:30 AM
#39387   horse, just chill out for awhile give me bontooth 02/25/15 03:10:01 AM